Filter Your Search

  • ?
    Participants who either do not have cancer but are at high risk for developing the disease or have had cancer and are at high risk for developing a new cancer.
  • ?
    These trials look at ways to improve the quality of life of cancer patients, especially those who have side effects from cancer and its treatment. They find new ways to help people cope with pain, nutrition problems, infection, nausea and vomiting, sleep disorders, depression and other health problems.
  • open for enrollment

    Ph Ib AMG 232 Concurrent W/ Preoperative Radiotherapy In Wild-Type P53 Soft Tissue Sarcoma (STS)

    Protocol: NRG-DT001

    Principal Investigator: Thomas J Scharschmidt, MD

    Learn More
  • open for enrollment

    Ph II Pembrolizumab w/ RT and Adj Pembrolizumab in Pts w/Soft Tissue Sarcoma of the Extremity

    Protocol: OSU-17015

    Principal Investigator: Gabriel Tinoco, MD

    Learn More
  • open for enrollment

    Ph 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

    Protocol: OSU-17043

    Principal Investigator: James L Chen, MD

    Learn More
  • open for enrollment

    KPT-330 Vs Placebo In Pts W/ Advanced Unresectable DDLS

    Protocol: OSU-17193

    Principal Investigator: James L Chen, MD

    Learn More
  • open for enrollment

    Ph I Dose Escalation & Cohort Expansion Study of TSR-042 in Pts w/ Advanced Solid Tumors

    Protocol: OSU-16293

    Principal Investigator: David M O'Malley, MD

    Learn More
  • open for enrollment

    Pilot Study Of Ny-Eso-1c259t In Subjects W/ Adv Myxoid/ Round Cell Liposarcoma

    Protocol: OSU-16142

    Principal Investigator: David Liebner, MD

    Learn More
  • open for enrollment

    Ph 1, BXQ-350 as a Single Agent by IV w/ Advanced Solid Tumors and Recurrent High-Grade Gliomas

    Protocol: OSU-16182

    Principal Investigator: Vinay K Puduvalli, MD

    Learn More
  • open for enrollment

    The OSU Comprehensive Cancer Center Malignant Melanoma Tissue Bank

    Protocol: OSU-18143

    Principal Investigator: William E Carson, III, MD

    Learn More
  • open for enrollment

    SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas

    Protocol: OSU-14056


    Inclusion Criteria:

    Patients must have histologically or cytologically confirmed advanced/metastatic

    liposarcoma, osteogenic sarcoma, or Ewing/Ewing-like sarcoma of soft tissue or bone.

    This study will accept the diagnosis made at the investigator's center.

    WHO Performance Status 0, 1 or 2. A maximum of 1/3 of patients in cohorts A & B may

    be WHO performance status 2.

    At least one prior line of systemic therapy for the sarcoma diagnosis (neoadjuvant,

    adjuvant or metastatic disease).

    All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v 4.0 Grade

    1 or less (except alopecia) at the time of signing the Informed Consent Form (ICF).

    Subject must be able to swallow and retain oral medication.

    At least one site of measurable disease on x-ray/CT/MRI scan as defined by RECIST

    1.1. Baseline imaging must be performed within 28 days of Day 1 of study.

    Adequate organ function within 14 days of registration INR (International Normalized

    Ratio) : patients with no prior evidence of underlying abnormality in coagulation

    parameters exists, according to the written documentation of the treating physician

    Evidence of progression of disease as defined by RECIST 1.1 (i.e. new disease sites

    or 30% growth of index lesions) within 6 months of registration

    Patients with central nervous system disease are eligible for enrollment if they have

    received prior radiotherapy or surgery to sites of CNS (central nervous system)

    metastatic disease and are without evidence of clinical progression for at least 12

    weeks after therapy.

    Exclusion Criteria:

    Patients with documentation of well differentiated liposarcoma only (of the well

    differentiated/dedifferentiated liposarcoma family) are specifically excluded, owing

    to its characteristically slow growth. If high grade areas are suspected

    (dedifferentiation), but not proved by pathology analysis (e.g. after primary

    resection of a well-differentiated liposarcoma), a biopsy must be performed to

    demonstrate the high-grade dedifferentiated disease.

    Prior systemic therapy with a small molecule oral kinase inhibitor, including but not

    limited to: pazopanib, sunitinib, sorafenib, everolimus, sirolimus, vemurafenib,


    Previous assignment to treatment during this study. Subjects permanently withdrawn

    from study participation will not be allowed to re-enter study. Patients who progress

    on placebo are specifically allowed to enroll on the treatment arm of the study if

    they meet all other entry criteria.

    Concurrent, clinically significant, active malignancies within 12 months of study


    Patients with severe and/or uncontrolled concurrent medical disease that in the

    opinion of the investigator could cause unacceptable safety risks or compromise

    compliance with the protocol.

    Major surgery within 28 days prior to study registration or those patients who have

    not recovered adequately from prior surgery

    Patients who have received wide field radiotherapy ≤ 28 days (defined as > 50% of

    volume of pelvis bones or equivalent) or limited field radiation for palliation < 14

    days prior to study registration or those patients who have not recovered adequately

    from side effects of such therapy.

    Patients who have received prior systemic therapy < 14 days prior to study

    registration or have not recovered adequately from toxicities to CTCAE v. 4.0 grade 1

    or less; prior investigational therapy may not have been given < 5 half-lives of last

    dose of treatment, or < 14 days, whichever is greater.

    Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm

    Hg [NCI-CTCAE v 4.0] on repeated measurement) despite optimal medical management.

    Active or clinically significant cardiac disease including: Congestive heart

    failure-New York Heart Association (NYHA) > class II, Active coronary artery disease,

    Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or

    digoxin, Unstable angina (anginal symptoms at rest), new onset angina within 3 months

    before randomization, or myocardial infarction within 6 months before


    Evidence or history of bleeding diathesis or coagulopathy

    Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to study


    Subjects with thrombotic, embolic, venous, or arterial events, such as

    cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis

    or pulmonary embolism within 6 months of start of study treatment

    Known history of human immunodeficiency virus (HIV) infection or current chronic or

    active hepatitis B or C infection requiring treatment with antiviral therapy.

    Ongoing infection > Grade 2 NCI-CTCAE v 4.0

    Presence of a non-healing wound, non-healing ulcer, or benign bone fracture (patients

    with stress insufficiency fractures e.g. from osteoporosis or pathological fracture

    from tumor are eligible for study)

    Patients with seizure disorder requiring medication

    Persistent proteinuria: Grade 3 NCI-CTCAE v 4.0 (> 3.5 g/24 h, measured by urine

    protein:creatinine ratio on a random urine sample)

    Interstitial lung disease with ongoing signs and symptoms at the time of informed


    Pleural effusion or ascites that causes respiratory compromise (≥ NCI-CTCAE version

    4.0 Grade 2 dyspnea)

    History of organ allograft (including corneal transplant).

    Known or suspected allergy or hypersensitivity to regorafenib, or excipients of the

    formulations given during the course of this trial.

    Any malabsorption condition.

    Women who are pregnant or breast-feeding.

    Any condition which, in the investigator's opinion, makes the subject unsuitable for

    trial participation.

    Substance abuse, medical, psychological or social conditions that may interfere with

    the subject's participation in the study or evaluation of the study results.

    Inability to comply with protocol required procedures.

    Use of any herbal remedy (e.g. St. John wort [Hypericum perforatum]).

    Principal Investigator: David Liebner, MD

    Learn More